When it comes to pharmacology, the big story these days is the development of the “glucagon-like peptide-1 (GLP-1) mimics,” ...
A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving ...
Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic ...
New research reveals these medications impact everything from heart health to restaurant menus.
GLP-1 receptor agonists increase hormones that help control hunger, satiety and blood sugar. They boost the release of insulin in the body when blood sugar rises, reduce glucagon (a hormone that ...
News-Medical.Net on MSN
NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in ...
CBeyondTM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring ...
Once-weekly semaglutide significantly reduces hospital admissions and total hospital stay in patients with CVD and obesity.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH ...
A significant portion of modern endocrine research involves Growth Hormone Secretagogues (GHS). These peptides are designed ...
Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease in the Western world, driven by obesity, insulin resistance, and systemic inflammation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results